Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: the national Israeli study of ovarian cancer - PubMed (original) (raw)
Comparative Study
Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: the national Israeli study of ovarian cancer
Angela Chetrit et al. J Clin Oncol. 2008.
Abstract
Purpose: To evaluate the long-term survival of ovarian cancer (OvC) patients in total and by BRCA1/2 mutation status.
Patients and methods: In a nationwide case-control study on OvC conducted in Israel between 1994 and 1999, 779 Jewish women with epithelial invasive OvC were tested for the three Ashkenazi Jewish founder mutations in BRCA1 (185delAG; 5382insC) and BRCA2 (6174delT) genes and followed for survival up to 2003. Of the 605 women of Ashkenazi origin, 213 (35.2%) carried a mutation in the BRCA1/2 genes. Clinical characteristics were abstracted from the patients' medical records. The Kaplan-Meier method, log-rank tests, and stepwise Cox regression model were used for survival analyses.
Results: The 5-year survival rate for the entire group was 39%. Median survival for carriers was significantly longer than for noncarriers (53.7 v 37.9 months, respectively; P = .002). This differential survival was pronounced among women diagnosed at stages III to IV (5-year survival rates of 38.1% and 24.5% for carriers and noncarriers, respectively; P < .001) and for women with poor grade (45.4% v 31.5%, for carriers and noncarriers, respectively; P < .001). These results remained significant after controlling for age at diagnosis, grade, and morphology. This benefit in prognosis was seen for both BRCA1 and BRCA2 carriers compared with noncarriers. During the study period (median follow-up, 6.2 years), being a BRCA1/2 mutation carrier decreased the mortality rate by 28%.
Conclusion: This study confirms that, among Ashkenazi OvC patients, BRCA1/2 mutations are associated with improved long-term survival. This may be due to distinct clinical behavior and/or to a better response to chemotherapy.
Comment in
- Is It time to stratify for BRCA mutation status in therapeutic trials in ovarian cancer?
Kauff ND. Kauff ND. J Clin Oncol. 2008 Jan 1;26(1):9-10. doi: 10.1200/JCO.2007.14.0244. J Clin Oncol. 2008. PMID: 18165631 No abstract available.
Similar articles
- Patients with double primary tumors in the breast and ovary- clinical characteristics and BRCA1-2 mutations status.
Fishman A, Dekel E, Chetrit A, Lerner-Geva L, Bar-Am A, Beck D, Beller U, Ben-Baruch G, Piura B, Friedman E, Struewing JP, Modan B. Fishman A, et al. Gynecol Oncol. 2000 Oct;79(1):74-8. doi: 10.1006/gyno.2000.5895. Gynecol Oncol. 2000. PMID: 11006035 - Ovarian cancer survival in Ashkenazi Jewish patients with BRCA1 and BRCA2 mutations.
Ramus SJ, Fishman A, Pharoah PD, Yarkoni S, Altaras M, Ponder BA. Ramus SJ, et al. Eur J Surg Oncol. 2001 Apr;27(3):278-81. doi: 10.1053/ejso.2000.1097. Eur J Surg Oncol. 2001. PMID: 11373105 - Founder mutations in BRCA1/2 are not frequent in Canadian Ashkenazi Jewish men with prostate cancer.
Hamel N, Kotar K, Foulkes WD. Hamel N, et al. BMC Med Genet. 2003 Aug 11;4:7. doi: 10.1186/1471-2350-4-7. BMC Med Genet. 2003. PMID: 12911837 Free PMC article. - Fallopian tube and primary peritoneal carcinomas associated with BRCA mutations.
Levine DA, Argenta PA, Yee CJ, Marshall DS, Olvera N, Bogomolniy F, Rahaman JA, Robson ME, Offit K, Barakat RR, Soslow RA, Boyd J. Levine DA, et al. J Clin Oncol. 2003 Nov 15;21(22):4222-7. doi: 10.1200/JCO.2003.04.131. J Clin Oncol. 2003. PMID: 14615451 Review. - Identification of germline 185delAG BRCA1 mutations in non-Jewish Americans of Spanish ancestry from the San Luis Valley, Colorado.
Mullineaux LG, Castellano TM, Shaw J, Axell L, Wood ME, Diab S, Klein C, Sitarik M, Deffenbaugh AM, Graw SL. Mullineaux LG, et al. Cancer. 2003 Aug 1;98(3):597-602. doi: 10.1002/cncr.11533. Cancer. 2003. PMID: 12879478 Review.
Cited by
- Antibody-Drug Conjugates and Their Potential in the Treatment of Patients with Biliary Tract Cancer.
Alexander S, Aleem U, Jacobs T, Frizziero M, Foy V, Hubner RA, McNamara MG. Alexander S, et al. Cancers (Basel). 2024 Sep 30;16(19):3345. doi: 10.3390/cancers16193345. Cancers (Basel). 2024. PMID: 39409965 Free PMC article. Review. - Deep Neural Network Integrated into Network-Based Stratification (D3NS): A Method to Uncover Cancer Subtypes from Somatic Mutations.
Valerio M, Inno A, Zambelli A, Cortesi L, Lorusso D, Viassolo V, Verzè M, Nicolis F, Gori S. Valerio M, et al. Cancers (Basel). 2024 Aug 14;16(16):2845. doi: 10.3390/cancers16162845. Cancers (Basel). 2024. PMID: 39199616 Free PMC article. - CA-125 KELIM as an Alternative Predictive Tool to Identify Which Patients Can Benefit from PARPi in High-Grade Serous Advanced Ovarian Cancer: A Retrospective Pilot Diagnostic Accuracy Study.
Zouzoulas D, Tsolakidis D, Tzitzis P, Chatzistamatiou K, Theodoulidis V, Sofianou I, Grimbizis G, Timotheadou E. Zouzoulas D, et al. Int J Mol Sci. 2024 May 11;25(10):5230. doi: 10.3390/ijms25105230. Int J Mol Sci. 2024. PMID: 38791269 Free PMC article. - Integrins as the pivotal regulators of cisplatin response in tumor cells.
Nasimi Shad A, Moghbeli M. Nasimi Shad A, et al. Cell Commun Signal. 2024 May 13;22(1):265. doi: 10.1186/s12964-024-01648-0. Cell Commun Signal. 2024. PMID: 38741195 Free PMC article. Review. - Analysis of BRCA1- and BRCA2-Related Pancreatic Cancer and Survival.
Boursi B, Wileyto EP, Mamtani R, Domchek SM, Golan T, Hood R, Reiss KA. Boursi B, et al. JAMA Netw Open. 2023 Nov 1;6(11):e2345013. doi: 10.1001/jamanetworkopen.2023.45013. JAMA Netw Open. 2023. PMID: 38010655 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous